Udvalget konkluderede, at fordelene ved Cystadane opvejer risiciene, når det anvendes i henhold til indikationen som tillægsbehandling ved homocystinuri.
The committee decided that Cystadane’ s benefits outweighed its risks in the adjunctive treatment of homocystinuria, when it is used according to its indication.